Clinical Trials
221 trialsScheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
Zhejiang University
GENE
Sir Run Run Shaw Hospital
SAFIR-ABC10
UNICANCER
SEVILLA
UNICANCER
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
CARPEGIEM
Hospital Universitari de Bellvitge
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Hospital Universitari de Bellvitge
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Tongji Hospital
MINIMUM
Oslo University Hospital
Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice
Fudan University
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
SHIELD
China Medical University, China
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
CROCOBIL
UNICANCER
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Shanghai Zhongshan Hospital
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
LenPac
National Health Research Institutes, Taiwan
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Fudan University
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
BRAVE
Aichi Medical University
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Peking Union Medical College Hospital
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
NIFE
AIO-Studien-gGmbH
COMBATBIL
University Hospital, Essen
LapTAP
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
XmAb20717 in Advanced Biliary Tract Cancers
Abramson Cancer Center at Penn Medicine
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
Stanford University
YJ-BTC
Fudan University
PILOT-BTC
Peking Union Medical College Hospital